Xometry, Inc.

XMTR

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$174.7M

1 fund

Feb 17, 2026

$118.1M

1 fund

-32% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 1,985,865Value: $118.1M

**Signal Note: Driehaus Capital Initiates $118M Position in Xometry** Driehaus Capital's entry into XMTR (a digital manufacturing platform, not a biotech drug developer) signals conviction in non-pharma growth despite sector volatility. This positioning is notable given Driehaus's significant biotech allocation, suggesting portfolio diversification into adjacent life sciences infrastructure rather than clinical-stage risk.

Eventide Asset ManagementNEWFeb 13, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AXON2 funds NVDA2 funds VEEV2 funds VCYT2 funds LBRT2 funds RMBS2 funds UNP2 funds LITE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**SIGNAL NOTE: Eventide initiates $174.7M position in Xometry** Xometry is a B2B manufacturing platform (not a biotech company), suggesting Eventide is diversifying beyond traditional drug development into healthcare-adjacent industrial services. This entry size indicates conviction in Xometry's unit economics and potential margin expansion as manufacturing automation accelerates, though the rationale diverges from Eventide's typical biotech/life sciences thesis.